Aarti Pharmalabs challenges Rs 59.5 cr stamp duty order in Gujarat HC

Regulatory & Legal View source PDF Explain this filing

AARTIPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.7%Reaction day

₹954.00

prior close

₹953.00

announcement price

After-mkt

timing

Nifty Microcap 250market-1.3%+4.0% vs market

Pharmaceuticals peers, median of 173sector-0.8%+3.5% vs sector

On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 3.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

-1.8

15m

-1.7

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.7-1.3+4.0-0.8+3.5

Next day

-0.8-1.3+0.5-1.3+0.5

+2.3+0.0+2.3-0.4+2.7

+0.1-0.2+0.3-0.1+0.2

-7.8-3.0-4.8-3.0-4.7

-10.0-2.7-7.2-3.1-6.9

-7.6-1.7-5.9-3.0-4.5

15d

-13.6-8.9-4.8-6.9-6.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aarti Pharmalabs has filed a writ petition in the Gujarat High Court challenging a Rs 59.50 crore stamp duty order (including penalties) from the Superintendent of Stamps, Gandhinagar. The levy relates to the company's demerger scheme sanctioned by the NCLT Ahmedabad bench in September 2022. The original order was passed on August 29, 2026, and the company is now legally contesting it.

Likely market impact

Material contingent liability if court upholds demand; currently disputed, may pressure stock sentiment until resolved.